|
1
|
Garraway LA: Genomics-driven oncology:
Framework for an emerging paradigm. J Clin Oncol. 31:1806–1814.
2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Blanke CD, Rankin C, Demetri GD, Ryan CW,
Von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki
RG, et al: Phase III randomized, intergroup trial assessing
imatinib mesylate at two dose levels in patients with unresectable
or metastatic gastrointestinal stromal tumors expressing the kit
receptor tyrosine kinase: S0033. J Clin Oncol. 26:626–632.
2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
MacConaill LE: Existing and emerging
technologies for tumor genomic profiling. J Clin Oncol.
31:1815–1824. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Luchini C, Lawlor RT, Milella M and Scarpa
A: Molecular tumor boards in clinical practice. Trends Cancer.
6:738–744. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Schwaederle M, Parker BA, Schwab RB, Fanta
PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC,
Ojeda-Fournier H, et al: Molecular tumor board: The University of
California-San Diego Moores cancer center experience. Oncologist.
19:631–636. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gray SW, Hicks-Courant K, Cronin A,
Rollins BJ and Weeks JC: Physicians' attitudes about multiplex
tumor genomic testing. J Clin Oncol. 32:1317–1323. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Vander Velden DL, Van Herpen CML, Van
Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM,
Langenberg MHG, Cuppen E, Sleijfer S, et al: Molecular tumor
boards: Current practice and future needs. Ann Oncol. 8:3070–3075.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Theelen WS, Mittempergher L, Willems SM,
Bosma AJ, Peters DD, van der Noort V, Japenga EJ, Peeters T, Koole
K, Šuštić T, et al: FGFR1, 2 and 3 protein overexpression and
molecular aberrations of FGFR3 in early stage non-small cell lung
cancer. J Pathol Clin Res Res. 2:223–233. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Goodsaid FM and Mendrick DL: Translational
medicine and the value of biomarker qualification. Sci Transl Med.
2(47ps44)2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ortiz MV, Kobos R, Walsh M, Slotkin EK,
Roberts S, Berger MF, Hameed M, Solit D, Ladanyi M, Shukla N and
Kentsis A: Integrating genomics into clinical pediatric oncology
using the molecular tumor board at the memorial sloan kettering
cancer center. Pediatr Blood Cancer. 63:1368–1374. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tobin NP, Foukakis T, De Petris L and
Bergh J: The importance of molecular markers for diagnosis and
selection of targeted treatments in patients with cancer. J Intern
Med. 278:545–570. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chinot OL, Wick W, Mason W, Henriksson R,
Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea
D, et al: Bevacizumab plus radiotherapy-temozolomide for newly
diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mardis ER: The translation of cancer
genomics: Time for a revolution in clinical cancer care. Genome
Med. 6(22)2014.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Andre F, Mardis E, Salm M, Soria JC, Siu
LL and Swanton C: Prioritizing targets for precision cancer
medicine. Ann Oncol. 25:2295–2303. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Aaltonen KE, Novosadová V, Bendahl PO,
Graffman C, Larsson AM and Rydén L: Molecular characterization of
circulating tumor cells from patients with metastatic breast cancer
reflects evolutionary changes in gene expression under the pressure
of systemic therapy. Oncotarget. 8:45544–45565. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hong X, Sullivan RJ, Kalinich M, Kwan TT,
Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner
BS, et al: Molecular signatures of circulating melanoma cells for
monitoring early response to immune checkpoint therapy. Proc Natl
Acad Sci USA. 115:2467–2472. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Egyud M, Tejani M, Pennathur A, Luketich
J, Sridhar P, Yamada E, Ståhlberg A, Filges S, Krzyzanowski P,
Jackson J, et al: Detection of circulating tumor DNA in plasma: A
potential biomarker for esophageal adenocarcinoma. Ann Thorac Surg.
108:343–349. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Francaviglia I, Magliacane G, Lazzari C,
Grassini G, Brunetto E, Dal Cin E, Girlando S, Medicina D, Smart
CE, Bulotta A, et al: Identification and monitoring of somatic
mutations in circulating cell-free tumor DNA in lung cancer
patients. Lung Cancer. 134:225–232. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tanos R and Thierry AR: Clinical relevance
of liquid biopsy for cancer screening. Transl Cancer Res. 7 (Suppl
2):S105–S129. 2018.
|
|
22
|
Thierry AR, El Messaoudi S, Gahan PB,
Anker P and Stroun M: Origins, structures, and functions of
circulating DNA in oncology. Cancer Metastasis Rev. 35:347–376.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fleischhacker M and Schmidt B: Circulating
nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta.
1775:181–232. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mouliere F, El Messaoudi S, Pang D,
Dritschilo A and Thierry AR: Multi-marker analysis of circulating
cell-free DNA toward personalized medicine for colorectal cancer.
Mol Oncol. 8:927–941. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhang Z, Fan W, Deng Q, Tang S, Wang P, Xu
P, Wang J and Yu M: The prognostic and diagnostic value of
circulating tumor cells in bladder cancer and upper tract
urothelial carcinoma: A meta-analysis of 30 published studies.
Oncotarget. 8:59527–59538. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hofman P: Liquid biopsy for early
detection of lung cancer. Curr Opin Oncol. 29:73–78.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tanaka F, Yoneda K, Kondo N, Hashimoto M,
Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T,
et al: Circulating tumor cell as a diagnostic marker in primary
lung cancer. Clin Cancer Res. 15:6980–6986. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Krishnamurthy N, Spencer E, Torkamani A
and Nicholson L: Liquid biopsies for cancer: Coming to a patient
near you. J Clin Med. 6(3)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Desmond-Hellmann S: Toward precision
medicine: A new social contract? Sci Transl Med.
4(129ed3)2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Heckman-Stoddard BM and Smith JJ:
Precision medicine clinical trials: Defining new treatment
strategies. In seminars in oncology nursing. Vol. 30. WB Saunders,
pp109-116, 2014.
|
|
31
|
Le Tourneau C, Kamal M, Tsimberidou AM,
Bedard P, Pierron G, Callens C, Rouleau E, Vincent-Salomon A,
Servant N, Alt M, et al: Treatment algorithms based on tumor
molecular profiling: The essence of precision medicine trials. J
Natl Cancer Inst. 108(v362)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ciriello G, Miller ML, Aksoy BA,
Senbabaoglu Y, Schultz N and Sander C: Emerging landscape of
oncogenic signatures across human cancers. Nat Genet. 45:1127–1133.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Berry DA: Adaptive clinical trials in
oncology. Nat Rev Clin Oncol. 9:199–207. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mazo C, Barron S, Mooney C and Gallagher
WM: Multi-gene prognostic signatures and prediction of pathological
complete response to neoadjuvant chemotherapy in ER-positive,
HER2-negative breast cancer patients. Cancers (Basel).
12(1133)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Uckun FM, Cogle CR, Lin TL, Qazi S, Trieu
VN, Schiller G and Watts JM: A phase 1B clinical study of
combretastatin A1 diphosphate (OXi4503) and cytarabine (ARA-C) in
combination (OXA) for patients with relapsed or refractory acute
myeloid leukemia. Cancers (Basel). 12(74)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Shao H, Chung J, Balaj L, Charest A,
Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R and
Lee H: Protein typing of circulating microvesicles allows real-time
monitoring of glioblastoma therapy. Nat Med. 18:1835–1840.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
37
|
Melo SA, Luecke LB, Kahlert C, Fernandez
AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari
N, et al: Glypican-1 identifies cancer exosomes and detects early
pancreatic cancer. Nature. 523:177–182. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Uckun FM, Qazi S, Hwang L and Trieu VN:
Recurrent or refractory high-grade gliomas treated by
convection-enhanced delivery of a TGFβ 2-targeting RNA therapeutic:
A post-hoc analysis with long-term follow-up. Cancers (Basel).
11(1892)2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kato T, Mizutani K, Kameyama K, Kawakami
K, Fujita Y, Nakane K, Kanimoto Y, Ehara H, Ito H, Seishima M, et
al: Serum exosomal P-glycoprotein is a potential marker to diagnose
docetaxel resistance and select a taxoid for patients with prostate
cancer. Urol Oncol. 33:385.e15–e20. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Koulis C, Yap R, Engel R, Jardé T, Wilkins
S, Solon G, Shapiro JD, Abud H and McMurrick P: Personalized
medicine-current and emerging predictive and prognostic biomarkers
in colorectal cancer. Cancers (Basel). 12(812)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Rexer BN and Arteaga CL: Intrinsic and
acquired resistance to HER2-targeted therapies in HER2
gene-amplified breast cancer: Mechanisms and clinical implications.
Crit Rev Oncog. 17:1–16. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Montermini L, Meehan B, Gamier D, Lee WJ,
Lee TH, Guha A, Al-Nedawi K and Rak J: Inhibition of oncogenic
epidermal growth factor receptor kinase triggers release of
exosome-like extracellular vesicles and impacts their
phosphoprotein and DNA content. J Biol Chem. 290:24534–24546.
2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Van Dommelen SM, van der Meel R, van
Solinge WW, Coimbra M, Vader P and Schiffelers RM: Cetuximab
treatment alters the content of extracellular vesicles released
from tumor cells. Nanomedicine (Lond). 11:881–890. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Douillard JY, Shepherd FA, Hirsh V, Mok T,
Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, et
al: Molecular predictors of outcome with gefitinib and docetaxel in
previously treated non-small-cell lung cancer: Data from the
randomized phase III INTEREST trial. J Clin Oncol. 28:744–752.
2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kim ES, Herbst RS, Wistuba II, Lee JJ,
Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr,
Gupta S, et al: The BATTLE trial: Personalizing therapy for lung
cancer. Cancer Discov. 1:44–53. 2011.PubMed/NCBI View Article : Google Scholar
|
